Latest Breaking News On - Sperogenix therapeutics - Page 1 : comparemela.com

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

United statesUnited kingdomSwitzerland generalShabir hashamDario eklundAndrew smithEva kaliasChiesi farmaceuticiAmerica to catalyst pharmaceuticals incLife science allianceNational institute for healthSanthera pharmaceuticals holdingCatalyst pharmaceuticals incExchange regulation ltdRegulatory agencySanthera pharmaceuticals holding ltd

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDennis riedlEva kaliasDario eklundShabir hashamChiesi farmaceuticiAndrew smithSanthera pharmaceuticalsChina national medical products administrationCatalyst pharmaceuticalsHead investor relations communicationsExchange regulationEuropean medicines agencyEuropean union summary of product characteristics

Santhera s vamorolone NDA receives priority review in China

Santhera has reported that the China NMPA granted priority review for a new drug application (NDA) for vamorolone for Duchenne muscular dystrophy.

United kingdomSperogenix therapeuticsDrug evaluation

Santhera Pharmaceuticals Holding AG: Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA

Santhera Pharmaceuticals Holding AG: Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland generalNorth lanarkshireUnited kingdomEva kaliasDennis riedlBreakthrough therapy programHead investor relations communicationsChina national medical products administrationSanthera pharmaceuticalsEuropean unionSanthera pharmaceuticals holdingSperogenix therapeuticsDrug evaluationLilly asia venturesMorningside venturesHead investor relations

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA -March 27, 2024 at 02:01 am EDT

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA -March 27, 2024 at 02:01 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited kingdomUnited statesNorth lanarkshireEva kaliasAmerica to catalyst pharmaceuticals incSanthera pharmaceuticals holdingDrug administrationRegulatory agencyBreakthrough therapy programSanthera pharmaceuticalsEuropean union summary of product characteristicsChina national medical products administrationGlobenewswire incEuropean medicines agencyLife science alliance